Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
10,154
archived clinical trials in
Other Indications

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
OptumCare Cancer Care at Fort Apache
mi
from
Las Vegas, NV
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
OptumCare Cancer Care at Fort Apache
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
Marshfield Medical Center-Marshfield
mi
from
Marshfield, WI
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Marshfield Medical Center-Marshfield
mi
from
Marshfield, WI
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
AdventHealth Infusion Center Asheville
mi
from
Asheville, NC
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
AdventHealth Infusion Center Asheville
mi
from
Asheville, NC
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
Feather River Cancer Center
mi
from
Chico, CA
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Feather River Cancer Center
mi
from
Chico, CA
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
AdventHealth Hendersonville
mi
from
Hendersonville, NC
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
AdventHealth Hendersonville
mi
from
Hendersonville, NC
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
Dayton Physician LLC-Miami Valley Hospital North
mi
from
Dayton, OH
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Dayton Physician LLC-Miami Valley Hospital North
mi
from
Dayton, OH
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
Marshfield Medical Center-Rice Lake
mi
from
Rice Lake, WI
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Marshfield Medical Center-Rice Lake
mi
from
Rice Lake, WI
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
mi
from
Jonesboro, AR
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
Regional Cancer Center at Indian Path Community Hospital
mi
from
Kingsport, TN
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Regional Cancer Center at Indian Path Community Hospital
mi
from
Kingsport, TN
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
Ascension Saint Mary's Hospital
mi
from
Saginaw, MI
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Ascension Saint Mary's Hospital
mi
from
Saginaw, MI
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
UH Seidman Cancer Center at Landerbrook Health Center
mi
from
Mayfield Heights, OH
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
UH Seidman Cancer Center at Landerbrook Health Center
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
UH Seidman Cancer Center at Lake Health Mentor Campus
mi
from
Mentor, OH
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
UH Seidman Cancer Center at Lake Health Mentor Campus
mi
from
Mentor, OH
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
UH Seidman Cancer Center at Southwest General Hospital
mi
from
Middleburg Heights, OH
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
UH Seidman Cancer Center at Southwest General Hospital
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
Sanford Roger Maris Cancer Center
mi
from
Fargo, ND
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Sanford Roger Maris Cancer Center
mi
from
Fargo, ND
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
Danville Regional Medical Center
mi
from
Danville, VA
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
Danville Regional Medical Center
mi
from
Danville, VA
Click here to add this to my saved trials
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
MercyOne Waterloo Medical Center
mi
from
Waterloo, IA
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
MercyOne Waterloo Medical Center
mi
from
Waterloo, IA
Click here to add this to my saved trials
Observational Study of Dental Outcomes in Head and Neck Cancer Patients
Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients
Status: Enrolling
Updated:  12/31/1969
University of Connecticut Health Center - School of Dental Medicine
mi
from
Farmington, CT
Observational Study of Dental Outcomes in Head and Neck Cancer Patients
Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients
Status: Enrolling
Updated: 12/31/1969
University of Connecticut Health Center - School of Dental Medicine
mi
from
Farmington, CT
Click here to add this to my saved trials
Observational Study of Dental Outcomes in Head and Neck Cancer Patients
Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Observational Study of Dental Outcomes in Head and Neck Cancer Patients
Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Observational Study of Dental Outcomes in Head and Neck Cancer Patients
Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients
Status: Enrolling
Updated:  12/31/1969
New York University College of Dentistry
mi
from
New York, NY
Observational Study of Dental Outcomes in Head and Neck Cancer Patients
Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients
Status: Enrolling
Updated: 12/31/1969
New York University College of Dentistry
mi
from
New York, NY
Click here to add this to my saved trials
Observational Study of Dental Outcomes in Head and Neck Cancer Patients
Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Carolinas Medical Center - Dental Clinic
mi
from
Charlotte, NC
Observational Study of Dental Outcomes in Head and Neck Cancer Patients
Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Carolinas Medical Center - Dental Clinic
mi
from
Charlotte, NC
Click here to add this to my saved trials
Observational Study of Dental Outcomes in Head and Neck Cancer Patients
Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients
Status: Enrolling
Updated:  12/31/1969
University of Pennsylvania School of Dental Medicine
mi
from
Philadelphia, PA
Observational Study of Dental Outcomes in Head and Neck Cancer Patients
Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients
Status: Enrolling
Updated: 12/31/1969
University of Pennsylvania School of Dental Medicine
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Observational Study of Dental Outcomes in Head and Neck Cancer Patients
Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients
Status: Enrolling
Updated:  12/31/1969
The University of North Carolina School of Dentistry
mi
from
Chapel Hill, NC
Observational Study of Dental Outcomes in Head and Neck Cancer Patients
Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients
Status: Enrolling
Updated: 12/31/1969
The University of North Carolina School of Dentistry
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy
Phase I Pilot Study Evaluating Vaginal Dilator Use and Toxicity Following Vaginal Brachytherapy
Status: Enrolling
Updated:  12/31/1969
Stanford University School of Medicine
mi
from
Stanford, CA
Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy
Phase I Pilot Study Evaluating Vaginal Dilator Use and Toxicity Following Vaginal Brachytherapy
Status: Enrolling
Updated: 12/31/1969
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
RA-2 13-cis Retinoic Acid (Isotretinoin)
A Pilot Trial of 13-cis Retinoic Acid (Isotretinoin) for the Treatment of Men With Oligoasthenoteratozoospermia
Status: Enrolling
Updated:  12/31/1969
University of Washington Medical Center
mi
from
Seattle, WA
RA-2 13-cis Retinoic Acid (Isotretinoin)
A Pilot Trial of 13-cis Retinoic Acid (Isotretinoin) for the Treatment of Men With Oligoasthenoteratozoospermia
Status: Enrolling
Updated: 12/31/1969
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin.
A Double-blinded Placebo-controlled Single-center Study to Evaluate the Efficacy of Intranasal Insulin 40 International Units Day as Treatment for Subjects With Parkinson Disease and Multiple System Atrophy
Status: Enrolling
Updated:  12/31/1969
Univ of Massachusetts Med School
mi
from
Worcester, MA
Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin.
A Double-blinded Placebo-controlled Single-center Study to Evaluate the Efficacy of Intranasal Insulin 40 International Units Day as Treatment for Subjects With Parkinson Disease and Multiple System Atrophy
Status: Enrolling
Updated: 12/31/1969
Univ of Massachusetts Med School
mi
from
Worcester, MA
Click here to add this to my saved trials
AM-101 in the Treatment of Acute Tinnitus 2
Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus 2
Status: Enrolling
Updated:  12/31/1969
Medpace
mi
from
Cincinnati, OH
AM-101 in the Treatment of Acute Tinnitus 2
Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus 2
Status: Enrolling
Updated: 12/31/1969
Medpace
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Post-market Clinical Follow-up of a Magnetic Bone Conduction Implant (Cochlear Baha Attract System)
Post-market Clinical Follow-up of a Magnetic Bone Conduction Implant (Cochlear Baha Attract System)
Status: Enrolling
Updated:  12/31/1969
Dr. Doug Backhus
mi
from
Seattle, WA
Post-market Clinical Follow-up of a Magnetic Bone Conduction Implant (Cochlear Baha Attract System)
Post-market Clinical Follow-up of a Magnetic Bone Conduction Implant (Cochlear Baha Attract System)
Status: Enrolling
Updated: 12/31/1969
Dr. Doug Backhus
mi
from
Seattle, WA
Click here to add this to my saved trials
Post-market Clinical Follow-up of a Magnetic Bone Conduction Implant (Cochlear Baha Attract System)
Post-market Clinical Follow-up of a Magnetic Bone Conduction Implant (Cochlear Baha Attract System)
Status: Enrolling
Updated:  12/31/1969
Christina Runge
mi
from
Milwaukee, WI
Post-market Clinical Follow-up of a Magnetic Bone Conduction Implant (Cochlear Baha Attract System)
Post-market Clinical Follow-up of a Magnetic Bone Conduction Implant (Cochlear Baha Attract System)
Status: Enrolling
Updated: 12/31/1969
Christina Runge
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Post-market Clinical Follow-up of a Magnetic Bone Conduction Implant (Cochlear Baha Attract System)
Post-market Clinical Follow-up of a Magnetic Bone Conduction Implant (Cochlear Baha Attract System)
Status: Enrolling
Updated:  12/31/1969
Dr. Myrthe Hol
mi
from
Nijmegen,
Post-market Clinical Follow-up of a Magnetic Bone Conduction Implant (Cochlear Baha Attract System)
Post-market Clinical Follow-up of a Magnetic Bone Conduction Implant (Cochlear Baha Attract System)
Status: Enrolling
Updated: 12/31/1969
Dr. Myrthe Hol
mi
from
Nijmegen,
Click here to add this to my saved trials
Red Cell Transfusion Goals in Patients With Acute Leukemias
Prospective Randomized Clinical Feasibility Study of Red Cell Transfusion Goals in Patients With Acute Leukemias
Status: Enrolling
Updated:  12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Red Cell Transfusion Goals in Patients With Acute Leukemias
Prospective Randomized Clinical Feasibility Study of Red Cell Transfusion Goals in Patients With Acute Leukemias
Status: Enrolling
Updated: 12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.
A Multi-Center, Open-Label, First-in-Human, Phase I Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO6839921, An MDM2 Antagonist, Following Intravenous Administration in Patients With Advanced Malignancies, Including Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
University of Colorado
mi
from
Aurora, CO
A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.
A Multi-Center, Open-Label, First-in-Human, Phase I Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO6839921, An MDM2 Antagonist, Following Intravenous Administration in Patients With Advanced Malignancies, Including Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.
A Multi-Center, Open-Label, First-in-Human, Phase I Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO6839921, An MDM2 Antagonist, Following Intravenous Administration in Patients With Advanced Malignancies, Including Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Washington University
mi
from
Saint Louis, MO
A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.
A Multi-Center, Open-Label, First-in-Human, Phase I Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO6839921, An MDM2 Antagonist, Following Intravenous Administration in Patients With Advanced Malignancies, Including Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.
A Multi-Center, Open-Label, First-in-Human, Phase I Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO6839921, An MDM2 Antagonist, Following Intravenous Administration in Patients With Advanced Malignancies, Including Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina Hollings Cancer Center
mi
from
Charleston, SC
A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.
A Multi-Center, Open-Label, First-in-Human, Phase I Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO6839921, An MDM2 Antagonist, Following Intravenous Administration in Patients With Advanced Malignancies, Including Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina Hollings Cancer Center
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.
A Multi-Center, Open-Label, First-in-Human, Phase I Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO6839921, An MDM2 Antagonist, Following Intravenous Administration in Patients With Advanced Malignancies, Including Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
University Health Network; Princess Margaret Hospital; Medical Oncology Dept
mi
from
Toronto,
A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.
A Multi-Center, Open-Label, First-in-Human, Phase I Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO6839921, An MDM2 Antagonist, Following Intravenous Administration in Patients With Advanced Malignancies, Including Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
University Health Network; Princess Margaret Hospital; Medical Oncology Dept
mi
from
Toronto,
Click here to add this to my saved trials
Randomized Trial Comparison of Ototoxicity Monitoring Programs
Comprehensive Ototoxicity Monitoring Program for VA: A Randomized Trial
Status: Enrolling
Updated:  12/31/1969
VA Portland Health Care System, Portland, OR
mi
from
Portland, OR
Randomized Trial Comparison of Ototoxicity Monitoring Programs
Comprehensive Ototoxicity Monitoring Program for VA: A Randomized Trial
Status: Enrolling
Updated: 12/31/1969
VA Portland Health Care System, Portland, OR
mi
from
Portland, OR
Click here to add this to my saved trials
A Safety Study of the Auditory Brainstem Implant for Pediatric Profoundly Deaf Patients
A Feasibility Study of the Placement, Use, and Safety of the Nucleus 24 Auditory Brainstem Implant in Non-Neurofibromatosis Type 2 (NF2) Pediatric Patients
Status: Enrolling
Updated:  12/31/1969
Keck School of Medicine of USC
mi
from
Los Angeles, CA
A Safety Study of the Auditory Brainstem Implant for Pediatric Profoundly Deaf Patients
A Feasibility Study of the Placement, Use, and Safety of the Nucleus 24 Auditory Brainstem Implant in Non-Neurofibromatosis Type 2 (NF2) Pediatric Patients
Status: Enrolling
Updated: 12/31/1969
Keck School of Medicine of USC
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Safety Study of the Auditory Brainstem Implant for Pediatric Profoundly Deaf Patients
A Feasibility Study of the Placement, Use, and Safety of the Nucleus 24 Auditory Brainstem Implant in Non-Neurofibromatosis Type 2 (NF2) Pediatric Patients
Status: Enrolling
Updated:  12/31/1969
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
A Safety Study of the Auditory Brainstem Implant for Pediatric Profoundly Deaf Patients
A Feasibility Study of the Placement, Use, and Safety of the Nucleus 24 Auditory Brainstem Implant in Non-Neurofibromatosis Type 2 (NF2) Pediatric Patients
Status: Enrolling
Updated: 12/31/1969
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
NeutraSal Treatment for Xerostomia in OSAS Patients Using CPAP Therapy
NeutraSal in the Management of Xerostomia in Obstructive Sleep Apnea Syndrome (OSAS) Patients Utilizing Continuous Positive Airway Pressure (CPAP) Therapy
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
NeutraSal Treatment for Xerostomia in OSAS Patients Using CPAP Therapy
NeutraSal in the Management of Xerostomia in Obstructive Sleep Apnea Syndrome (OSAS) Patients Utilizing Continuous Positive Airway Pressure (CPAP) Therapy
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)
Pilot Study of the Effect of Vorinostat on Nervous System Hemangioblastomas In Von Hippel-Lindau Disease
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)
Pilot Study of the Effect of Vorinostat on Nervous System Hemangioblastomas In Von Hippel-Lindau Disease
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Aneuploidy Rates in Advanced Maternal Age Patients Supplemented With Coenzyme Q10 (CoQ10) Versus Those That Are Not: a Pilot Study
Blastocyst Aneuploidy Rates From Advanced Maternal Age Patients Supplemented With Coenzyme Q10 (CoQ10) Versus Those That Are Not: a Pilot Study
Status: Enrolling
Updated:  12/31/1969
REACh
mi
from
Charlotte, NC
Aneuploidy Rates in Advanced Maternal Age Patients Supplemented With Coenzyme Q10 (CoQ10) Versus Those That Are Not: a Pilot Study
Blastocyst Aneuploidy Rates From Advanced Maternal Age Patients Supplemented With Coenzyme Q10 (CoQ10) Versus Those That Are Not: a Pilot Study
Status: Enrolling
Updated: 12/31/1969
REACh
mi
from
Charlotte, NC
Click here to add this to my saved trials
AM-101 in the Treatment of Post-Acute Tinnitus 1
AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 1 (AMPACT1) - an Open-Label Extension to the TACTT2 Study
Status: Enrolling
Updated:  12/31/1969
Medpace
mi
from
Cincinnati, OH
AM-101 in the Treatment of Post-Acute Tinnitus 1
AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 1 (AMPACT1) - an Open-Label Extension to the TACTT2 Study
Status: Enrolling
Updated: 12/31/1969
Medpace
mi
from
Cincinnati, OH
Click here to add this to my saved trials
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1
A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas
Status: Enrolling
Updated:  12/31/1969
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1
A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas
Status: Enrolling
Updated: 12/31/1969
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1
A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas
Status: Enrolling
Updated:  12/31/1969
University of Chicago
mi
from
Chicago, IL
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1
A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas
Status: Enrolling
Updated: 12/31/1969
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1
A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas
Status: Enrolling
Updated:  12/31/1969
Indiana Unversity
mi
from
Indianapolis, IN
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1
A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas
Status: Enrolling
Updated: 12/31/1969
Indiana Unversity
mi
from
Indianapolis, IN
Click here to add this to my saved trials
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1
A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas
Status: Enrolling
Updated:  12/31/1969
National Cancer Institute (NCI)
mi
from
Bethesda, MD
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1
A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas
Status: Enrolling
Updated: 12/31/1969
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Click here to add this to my saved trials
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1
A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas
Status: Enrolling
Updated:  12/31/1969
Children's Hospital Boston
mi
from
Boston, MA
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1
A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas
Status: Enrolling
Updated: 12/31/1969
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1
A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas
Status: Enrolling
Updated:  12/31/1969
New York Univ. Medical Center
mi
from
New York, NY
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1
A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas
Status: Enrolling
Updated: 12/31/1969
New York Univ. Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1
A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1
A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1
A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1
A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1
A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas
Status: Enrolling
Updated:  12/31/1969
University of Utah
mi
from
Salt Lake City, UT
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1
A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas
Status: Enrolling
Updated: 12/31/1969
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials